CDK4-话题@MedSci

#CDK4#

49篇内容 | 883人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1703120, encodeId=fc511e03120f3, content=<a href='/topic/show?id=98b24402bb' target=_blank style='color:#2F92EE;'>#CDK4#</a>, objectTitle=HR+HER2-晚期乳腺癌CDK4/6i失败后治疗模式新探索, objectType=article, longId=736714, objectId=1cd4e36714ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1cd4e36714ec, replyNumber=0, likeNumber=65, createdTime=2023-02-27, rootId=0, userName=soongzhihua, userId=166330479856, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1cd4e36714ec, moduleTitle=HR+HER2-晚期乳腺癌CDK4/6i失败后治疗模式新探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1cd4e36714ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703117, encodeId=b2c61e03117d5, content=<a href='/topic/show?id=98b24402bb' target=_blank style='color:#2F92EE;'>#CDK4#</a>, objectTitle=ASCO 2022 | PALOMA-2研究最终数据出炉：全球首款CDK4/6抑制剂哌柏西利再受挫！ , objectType=article, longId=729095, objectId=d5c5e2909563, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5c5e2909563, replyNumber=0, likeNumber=40, createdTime=2022-08-04, rootId=0, userName=soongzhihua, userId=166330479856, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5c5e2909563, moduleTitle=ASCO 2022 | PALOMA-2研究最终数据出炉：全球首款CDK4/6抑制剂哌柏西利再受挫！ , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5c5e2909563)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703119, encodeId=521c1e0311927, content=<a href='/topic/show?id=98b24402bb' target=_blank style='color:#2F92EE;'>#CDK4#</a>, objectTitle=CDK4/6i不良反应管理手册来了！这篇总结的很全哦~, objectType=article, longId=733755, objectId=afe2e3375555, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=afe2e3375555, replyNumber=0, likeNumber=47, createdTime=2022-10-03, rootId=0, userName=soongzhihua, userId=166330479856, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=afe2e3375555, moduleTitle=CDK4/6i不良反应管理手册来了！这篇总结的很全哦~, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=afe2e3375555)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703118, encodeId=82921e0311864, content=<a href='/topic/show?id=98b24402bb' target=_blank style='color:#2F92EE;'>#CDK4#</a>, objectTitle=Clin Cancer Res：氟维司群联合维奈托克治疗CDK4/6抑制剂难治性ER+转移性乳腺癌, objectType=article, longId=730361, objectId=69abe303613d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69abe303613d, replyNumber=0, likeNumber=34, createdTime=2022-11-29, rootId=0, userName=soongzhihua, userId=166330479856, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69abe303613d, moduleTitle=Clin Cancer Res：氟维司群联合维奈托克治疗CDK4/6抑制剂难治性ER+转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69abe303613d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703116, encodeId=726e1e03116db, content=<a href='/topic/show?id=98b24402bb' target=_blank style='color:#2F92EE;'>#CDK4#</a>, objectTitle=ASCO 2022 | MAINTAIN全新思路：CDK4/6抑制剂失败后跨线再战，瑞博西利仍可带来PFS获益！, objectType=article, longId=729096, objectId=317ae2909688, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=317ae2909688, replyNumber=0, likeNumber=50, createdTime=2023-05-08, rootId=0, userName=soongzhihua, userId=166330479856, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=317ae2909688, moduleTitle=ASCO 2022 | MAINTAIN全新思路：CDK4/6抑制剂失败后跨线再战，瑞博西利仍可带来PFS获益！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=317ae2909688)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703115, encodeId=b97e1e0311528, content=<a href='/topic/show?id=98b24402bb' target=_blank style='color:#2F92EE;'>#CDK4#</a>, objectTitle=LEUKEMIA：Erk1/2i 和 CDK4/6i 联合治疗复发难治性多发性骨髓瘤, objectType=article, longId=299159, objectId=5c4f2991594a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c4f2991594a, replyNumber=0, likeNumber=39, createdTime=2022-07-16, rootId=0, userName=soongzhihua, userId=166330479856, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c4f2991594a, moduleTitle=LEUKEMIA：Erk1/2i 和 CDK4/6i 联合治疗复发难治性多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c4f2991594a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703114, encodeId=ec561e0311484, content=<a href='/topic/show?id=98b24402bb' target=_blank style='color:#2F92EE;'>#CDK4#</a>, objectTitle=Br J Cancer：CDK4/6抑制剂在恶性胸膜间皮瘤临床前模型中的疗效分析, objectType=article, longId=219389, objectId=f5d0219389bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5d0219389bc, replyNumber=0, likeNumber=32, createdTime=2021-12-08, rootId=0, userName=soongzhihua, userId=166330479856, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5d0219389bc, moduleTitle=Br J Cancer：CDK4/6抑制剂在恶性胸膜间皮瘤临床前模型中的疗效分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5d0219389bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703109, encodeId=a2641e03109e1, content=<a href='/topic/show?id=98b24402bb' target=_blank style='color:#2F92EE;'>#CDK4#</a>, objectTitle=科学致胜，共克癌症 ——全球CDK4/6抑制剂持续响应“世界癌症日” 助力中国患者对抗晚期乳腺癌, objectType=article, longId=206821, objectId=c8452068210e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8452068210e, replyNumber=0, likeNumber=31, createdTime=2022-01-04, rootId=0, userName=soongzhihua, userId=166330479856, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8452068210e, moduleTitle=科学致胜，共克癌症 ——全球CDK4/6抑制剂持续响应“世界癌症日” 助力中国患者对抗晚期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c8452068210e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703110, encodeId=d9a41e03110ae, content=<a href='/topic/show?id=98b24402bb' target=_blank style='color:#2F92EE;'>#CDK4#</a>, objectTitle=JNCCN：乳腺癌患者CDK4/6抑制剂哌柏西利进展后使用阿贝西利治疗的疗效：多中心临床经验, objectType=article, longId=211171, objectId=30eb2111e1ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30eb2111e1ef, replyNumber=0, likeNumber=36, createdTime=2022-03-20, rootId=0, userName=soongzhihua, userId=166330479856, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30eb2111e1ef, moduleTitle=JNCCN：乳腺癌患者CDK4/6抑制剂哌柏西利进展后使用阿贝西利治疗的疗效：多中心临床经验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30eb2111e1ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703113, encodeId=d9e81e0311356, content=<a href='/topic/show?id=98b24402bb' target=_blank style='color:#2F92EE;'>#CDK4#</a>, objectTitle=2021BOC/BOA：殷咏梅教授解读CDK4/6抑制剂阿贝西利中国临床实践数据，以期提高可及性, objectType=article, longId=211179, objectId=0aac2111e9ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0aac2111e9ad, replyNumber=0, likeNumber=57, createdTime=2022-03-13, rootId=0, userName=soongzhihua, userId=166330479856, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0aac2111e9ad, moduleTitle=2021BOC/BOA：殷咏梅教授解读CDK4/6抑制剂阿贝西利中国临床实践数据，以期提高可及性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0aac2111e9ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703111, encodeId=cfc11e03111d1, content=<a href='/topic/show?id=98b24402bb' target=_blank style='color:#2F92EE;'>#CDK4#</a>, objectTitle=Clin Cancer Res:瑞博西尼（ribociclib）联合依西美坦+依维莫司治疗CDK4/6抑制剂治疗进展的HR+/HER2-晚期乳腺癌的疗效和安全性：I/II期TRINITI-1研究, objectType=article, longId=213367, objectId=676e21336e25, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=676e21336e25, replyNumber=0, likeNumber=57, createdTime=2021-11-17, rootId=0, userName=soongzhihua, userId=166330479856, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=676e21336e25, moduleTitle=Clin Cancer Res:瑞博西尼（ribociclib）联合依西美坦+依维莫司治疗CDK4/6抑制剂治疗进展的HR+/HER2-晚期乳腺癌的疗效和安全性：I/II期TRINITI-1研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=676e21336e25)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703112, encodeId=301e1e03112ec, content=<a href='/topic/show?id=98b24402bb' target=_blank style='color:#2F92EE;'>#CDK4#</a>, objectTitle=2021BOC/BOA：江泽飞教授解读CDK4/6抑制剂阿贝西利中国数据，期待惠及更多乳腺癌患者, objectType=article, longId=210931, objectId=06062109315d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06062109315d, replyNumber=0, likeNumber=28, createdTime=2022-01-12, rootId=0, userName=soongzhihua, userId=166330479856, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06062109315d, moduleTitle=2021BOC/BOA：江泽飞教授解读CDK4/6抑制剂阿贝西利中国数据，期待惠及更多乳腺癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=06062109315d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703107, encodeId=6d741e031071a, content=<a href='/topic/show?id=98b24402bb' target=_blank style='color:#2F92EE;'>#CDK4#</a>, objectTitle=Brit J Cancer：CDK4/6抑制剂可用于儿科和成人生殖细胞瘤治疗 , objectType=article, longId=195525, objectId=b61e195525f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b61e195525f3, replyNumber=0, likeNumber=37, createdTime=2021-01-28, rootId=0, userName=soongzhihua, userId=166330479856, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b61e195525f3, moduleTitle=Brit J Cancer：CDK4/6抑制剂可用于儿科和成人生殖细胞瘤治疗 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b61e195525f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703108, encodeId=f9431e03108bc, content=<a href='/topic/show?id=98b24402bb' target=_blank style='color:#2F92EE;'>#CDK4#</a>, objectTitle=甘李药业CDK4/6抑制剂获FDA孤儿药资格，治疗恶性胶质瘤, objectType=article, longId=200588, objectId=285f20058863, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=285f20058863, replyNumber=0, likeNumber=30, createdTime=2021-05-08, rootId=0, userName=soongzhihua, userId=166330479856, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=285f20058863, moduleTitle=甘李药业CDK4/6抑制剂获FDA孤儿药资格，治疗恶性胶质瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=285f20058863)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703106, encodeId=dbb31e031069f, content=<a href='/topic/show?id=98b24402bb' target=_blank style='color:#2F92EE;'>#CDK4#</a>, objectTitle=Cell Death Dis：CDK4/6抑制剂联合PARP抑制剂或可进一步提高乳腺癌的治疗效果, objectType=article, longId=192539, objectId=63c019253993, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63c019253993, replyNumber=0, likeNumber=45, createdTime=2020-09-20, rootId=0, userName=soongzhihua, userId=166330479856, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63c019253993, moduleTitle=Cell Death Dis：CDK4/6抑制剂联合PARP抑制剂或可进一步提高乳腺癌的治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63c019253993)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703104, encodeId=18881e03104f6, content=<a href='/topic/show?id=98b24402bb' target=_blank style='color:#2F92EE;'>#CDK4#</a>, objectTitle=诺华的CDK4/6抑制剂Kisquali治疗晚期或转移的乳腺癌临床试验成功, objectType=article, longId=184839, objectId=a8c018483912, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8c018483912, replyNumber=0, likeNumber=47, createdTime=2020-11-14, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8c018483912, moduleTitle=诺华的CDK4/6抑制剂Kisquali治疗晚期或转移的乳腺癌临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8c018483912)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703102, encodeId=13071e03102a4, content=<a href='/topic/show?id=98b24402bb' target=_blank style='color:#2F92EE;'>#CDK4#</a>, objectTitle=CDK4/6抑制剂哌柏西利给HR+晚期乳腺癌患者更长生存、更好生活, objectType=article, longId=184135, objectId=48f018413537, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48f018413537, replyNumber=0, likeNumber=31, createdTime=2020-07-31, rootId=0, userName=soongzhihua, userId=166330479856, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48f018413537, moduleTitle=CDK4/6抑制剂哌柏西利给HR+晚期乳腺癌患者更长生存、更好生活, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=48f018413537)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703101, encodeId=6cb41e0310148, content=<a href='/topic/show?id=98b24402bb' target=_blank style='color:#2F92EE;'>#CDK4#</a>, objectTitle=氟维司群联合CDK4/6i改写HR+/HER2+晚期乳腺癌治疗模式, objectType=article, longId=180695, objectId=da1a180695a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da1a180695a6, replyNumber=0, likeNumber=31, createdTime=2020-08-10, rootId=0, userName=soongzhihua, userId=166330479856, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da1a180695a6, moduleTitle=氟维司群联合CDK4/6i改写HR+/HER2+晚期乳腺癌治疗模式, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da1a180695a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703105, encodeId=9d991e0310571, content=<a href='/topic/show?id=98b24402bb' target=_blank style='color:#2F92EE;'>#CDK4#</a>, objectTitle=辉瑞的CDK4/6抑制剂Ibrance，获英国NICE批准治疗乳腺癌, objectType=article, longId=186505, objectId=22ce186505e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22ce186505e0, replyNumber=0, likeNumber=46, createdTime=2020-08-27, rootId=0, userName=soongzhihua, userId=166330479856, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22ce186505e0, moduleTitle=辉瑞的CDK4/6抑制剂Ibrance，获英国NICE批准治疗乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=22ce186505e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703091, encodeId=8e0e1e03091c5, content=<a href='/topic/show?id=98b24402bb' target=_blank style='color:#2F92EE;'>#CDK4#</a>, objectTitle=2019ASCO：诺华的CDK4/6抑制剂Kisqali在III期晚期乳腺癌试验中提前到达终点, objectType=article, longId=167612, objectId=933416e61276, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=933416e61276, replyNumber=0, likeNumber=35, createdTime=2020-04-01, rootId=0, userName=soongzhihua, userId=166330479856, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=933416e61276, moduleTitle=2019ASCO：诺华的CDK4/6抑制剂Kisqali在III期晚期乳腺癌试验中提前到达终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=933416e61276)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CDK4

2020-05-29

soongzhihua (审核中...)

前往app查看评论内容

#CDK4#

HR+HER2-晚期乳腺癌CDK4/6i失败后治疗模式新探索

2023-02-27

soongzhihua (审核中...)

前往app查看评论内容

#CDK4#

ASCO 2022 | PALOMA-2研究最终数据出炉：全球首款CDK4/6抑制剂哌柏西利再受挫！

2022-08-04

soongzhihua (审核中...)

前往app查看评论内容

#CDK4#

CDK4/6i不良反应管理手册来了！这篇总结的很全哦~

2022-10-03

soongzhihua (审核中...)

前往app查看评论内容

#CDK4#

Clin Cancer Res：氟维司群联合维奈托克治疗CDK4/6抑制剂难治性ER+转移性乳腺癌

2022-11-29

soongzhihua (审核中...)

前往app查看评论内容

#CDK4#

ASCO 2022 | MAINTAIN全新思路：CDK4/6抑制剂失败后跨线再战，瑞博西利仍可带来PFS获益！

2023-05-08

soongzhihua (审核中...)

前往app查看评论内容

#CDK4#

LEUKEMIA：Erk1/2i 和 CDK4/6i 联合治疗复发难治性多发性骨髓瘤

2022-07-16

soongzhihua (审核中...)

前往app查看评论内容

#CDK4#

Br J Cancer：CDK4/6抑制剂在恶性胸膜间皮瘤临床前模型中的疗效分析

2021-12-08

soongzhihua (审核中...)

前往app查看评论内容

#CDK4#

科学致胜，共克癌症 ——全球CDK4/6抑制剂持续响应“世界癌症日” 助力中国患者对抗晚期乳腺癌

2022-01-04

soongzhihua (审核中...)

前往app查看评论内容

#CDK4#

JNCCN：乳腺癌患者CDK4/6抑制剂哌柏西利进展后使用阿贝西利治疗的疗效：多中心临床经验

2022-03-20

soongzhihua (审核中...)

前往app查看评论内容

#CDK4#

2021BOC/BOA：殷咏梅教授解读CDK4/6抑制剂阿贝西利中国临床实践数据，以期提高可及性

2022-03-13

soongzhihua (审核中...)

前往app查看评论内容

#CDK4#

Clin Cancer Res:瑞博西尼（ribociclib）联合依西美坦+依维莫司治疗CDK4/6抑制剂治疗进展的HR+/HER2-晚期乳腺癌的疗效和安全性：I/II期TRINITI-1研究

2021-11-17

soongzhihua (审核中...)

前往app查看评论内容

#CDK4#

2021BOC/BOA：江泽飞教授解读CDK4/6抑制剂阿贝西利中国数据，期待惠及更多乳腺癌患者

2022-01-12

soongzhihua (审核中...)

前往app查看评论内容

#CDK4#

Brit J Cancer：CDK4/6抑制剂可用于儿科和成人生殖细胞瘤治疗

2021-01-28

soongzhihua (审核中...)

前往app查看评论内容

#CDK4#

甘李药业CDK4/6抑制剂获FDA孤儿药资格，治疗恶性胶质瘤

2021-05-08

soongzhihua (审核中...)

前往app查看评论内容

#CDK4#

Cell Death Dis：CDK4/6抑制剂联合PARP抑制剂或可进一步提高乳腺癌的治疗效果

2020-09-20

智慧医人 (审核中...)

前往app查看评论内容

#CDK4#

诺华的CDK4/6抑制剂Kisquali治疗晚期或转移的乳腺癌临床试验成功

2020-11-14

soongzhihua (审核中...)

前往app查看评论内容

#CDK4#

CDK4/6抑制剂哌柏西利给HR+晚期乳腺癌患者更长生存、更好生活

2020-07-31

soongzhihua (审核中...)

前往app查看评论内容

#CDK4#

氟维司群联合CDK4/6i改写HR+/HER2+晚期乳腺癌治疗模式

2020-08-10

soongzhihua (审核中...)

前往app查看评论内容

#CDK4#

辉瑞的CDK4/6抑制剂Ibrance，获英国NICE批准治疗乳腺癌

2020-08-27

soongzhihua (审核中...)

前往app查看评论内容

#CDK4#

2019ASCO：诺华的CDK4/6抑制剂Kisqali在III期晚期乳腺癌试验中提前到达终点

2020-04-01

科室
- - 订阅+
  - 更多科室
工具
服务